Clinical improvement (Mayo score) (9 weeks) · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes clinical improvement (Mayo score) (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Quality of life · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events (9 weeks) · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes total adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more exacerbations treated… compared with placebo (high certainty).
1 finding from 1 review
Patients with severe exacerbations (requiring hospitalisation or ER visit) · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more exacerbations requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Asthma control · children and adults with predominantly mild to moderate asthma
1 finding from 1 review
FEV1 % predicted · children and adults with predominantly mild to moderate asthma
1 finding from 1 review
Proportion of participants with one or more serious adverse events due to any cause · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more serious adverse events… compared with placebo (high certainty).
1 finding from 1 review
People with fatal asthma exacerbation. · children and adults with predominantly mild to moderate asthma
1 finding from 1 review
Withdrawals (parallel group trials/first arm cross‐over trials) · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in withdrawals from trial compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 ‐ total compared with placebo or standard care alone (high certainty).
1 finding from 1 review
Quality of life, · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · individuals with moderate to severe disease
1 finding from 1 review
Serious adverse events · individuals with moderate to severe disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes serious adverse events compared with standard plasma (very low certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 compared with human immunoglobulin (low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found